DUSP6 and neoplasm: Assessing 19 PDX tumour models, the combination of cetuximab and trametinib (i) yielded a high therapeutic efficacy, reaching disease control [either partial response (PR) or stable disease (SD)] in 14 of the 19 models (74%) tested, (ii) was on target concerning ERK and DUSP6, and (iii) rarely led to the development of SR in models with PR.